Vitamin E and Reduced Controlled Attenuation Parameter Score

Doses used in studies

mg/day: 800 (median 800, IQR 800–800) — 1 study

Time to effect

Median: 5.6 months · IQR 5.6 months–5.6 months · Range 5.6 months–5.6 months — Reported in 1 of 1 study

1 of 1 paper

Comparative efficacy of febuxostat and vitamin E in the management of MASLD: Insights from a randomized parallel clinical study.

2025-08
RCT · n = 32
European journal of pharmacology 1000
- Hadier El-Sheikh
- Sahar El-Haggar
- Rehab Badawi
- Eslam Habba

PubMed: 40383220
DOI: 10.1016/j.ejphar.2025.177735

9 Insights on

Reduced Controlled Attenuation Parameter Score

High evidence
Clinical

Both groups showed a significant reduction in CAP scores, with more pronounced decrease in vitamin E group (p < 0.001) compared to febuxostat group (p = 0.001).

Effect: Beneficial
Effect size: Large
Significant: Yes
Dose: 400 mg twice daily